Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world camrelizumab in hepatobiliary and pancreatic malignancies
ChiCTR2100049179Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatobiliary cancer (HBC), pancreatic cancer (PC), hepatocellular carcinoma (HCC) and 2 more, sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Objective response rate, Progression-free survival and 3 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatobiliary cancer (HBC)pancreatic cancer (PC)hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2100049179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049179.